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Abstract
There is an urgent need for rapid and accurate diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis (MDR-TB). No
diagnostic algorithm has been validated in this population. We hypothesized that pncA sequencing added to rpoB mutation analysis can
accurately identify patients with pyrazinamide-resistant MDR-TB. We identiﬁed from the Dutch national database (2007–11) patients with a
positive Mycobacterium tuberculosis culture containing a mutation in the rpoB gene. In these cases, we prospectively sequenced the pncA gene.
Results from the rpoB and pncA mutation analysis (pncA added to rpoB) were compared with phenotypic susceptibility testing results to
rifampicin, isoniazid and pyrazinamide (reference standard) using the Mycobacterial Growth Indicator Tube 960 system. We included 83
clinical M. tuberculosis isolates containing rpoB mutations in the primary analysis. Rifampicin resistance was seen in 72 isolates (87%), isoniazid
resistance in 73 isolates (88%) and MDR-TB in 65 isolates (78%). Phenotypic reference testing identiﬁed pyrazinamide-resistant MDR-TB in
31 isolates (48%). Sensitivity of pncA sequencing added to rpoB mutation analysis for detecting pyrazinamide-resistant MDR-TB was 96.8%,
the speciﬁcity was 94.2%, the positive predictive value was 90.9%, the negative predictive value was 98.0%, the positive likelihood was 16.8
and the negative likelihood was 0.03. In conclusion, pyrazinamide-resistant MDR-TB can be accurately detected using pncA sequencing added
to rpoB mutation analysis. We propose to include pncA sequencing in every isolate with an rpoB mutation, allowing for stratiﬁcation of
MDR-TB treatment according to pyrazinamide susceptibility.
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Introduction
Pyrazinamide-based treatment of multidrug-resistant tubercu-
losis (MDR-TB) has been the standard in the past decades and
its importance has become clearer in recent years [1]. Studies
have suggested that pyrazinamide might work synergistically
with other anti-TB drugs such as ﬂuoroquinolones and
bedaquiline [2,3]. Moreover, combining pyrazinamide in new
anti-TB treatment regimens might have the potential to
shorten MDR-TB treatment duration [3].
Despite this potential for pyrazinamide in MDR-TB treat-
ment, the high prevalence of pyrazinamide resistance in
MDR-TB [4] and the troublesome drug susceptibility testing
(DST) to pyrazinamide [5] have dampened enthusiasm. Phe-
notypic DST using the Mycobacterial Growth Indicator Tube
(MGIT) 960 system is currently considered the gold standard,
but it is prone to false-resistance errors [6]. Screening for
mutations in the pncA gene might be an alternative proxy for
pyrazinamide resistance [5]. Indeed, a recent meta-analysis has
suggested that within an MDR-TB population, pncA sequencing
has a good diagnostic accuracy [4].
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Sequencing the pncA gene might therefore prove to be the
DST assay to guide pyrazinamide-based MDR-TB treatment.
However, no formal study has been published evaluating the
accuracy of such a molecular-based diagnosis of pyrazinamide
resistance in MDR-TB. We hypothesized that pncA sequencing
added to rpoB mutation analysis can accurately identify these
pyrazinamide-resistant MDR-TB patients. We chose rpoB
mutation analysis because this may be a good indicator for
MDR-TB in high-burden settings [7]. To test our hypothesis,
we prospectively sequenced the pncA gene in patient isolates
with a known rpoB mutation and compared results with
phenotypic drug susceptibility results to rifampicin, isoniazid
and pyrazinamide.
Materials and Methods
Study setting
This study was performed at the National Institute for Public
Health and the Environment (RIVM), which receives nearly all
Mycobacterium tuberculosis complex isolates from the Nether-
lands [8]. Yearly, around 1–2% of all TB notiﬁcations in the
Netherlands are considered to be MDR-TB [8]. Pyrazinamide
resistance in the Netherlands is detected in 1% of all TB
cultures [6] and in 23% of MDR-TB cases [9].
Study population
We retrospectively identiﬁed from our national database
(2007–11) all patients with a positiveM. tuberculosis culture con-
taining an rpoB mutation (rpoB+ patients). We used the
Genotype MTBDRplus kit (Hain Lifesciences, Nehren,
Germany) to screen for mutations in the rpoB gene. If an rpoB
mutation was found by the line probe assay, the hotspot
region of the rpoB gene was sequenced as previously
described [10].
Phenotypic drug susceptibility testing
We tested susceptibility to rifampicin, isoniazid and pyrazin-
amide in all rpoB+ patients using the MGIT 960 system (Becton
Dickinson, Erembodegem, Belgium). Breakpoint concentra-
tions were set at 1.0 mg/L (rifampicin), 0.1 mg/L (isoniazid)
and 100 mg/L (pyrazinamide), according to the manufacturer’s
instruction. The DST results for rifampicin and isoniazid
resistance were extracted from our database for a ﬁrst
available isolate of an rpoB+ patient. DST to these anti-TB
drugs had been tested before this study within the context of
routine diagnostic service. MDR-TB was deﬁned as isolates
being resistant at least to rifampicin and isoniazid [1].
For susceptibility testing to pyrazinamide, cultures from
rpoB+ patients were obtained from our 70°C freezer and
sub-cultured in MGIT medium. Five experienced technicians
prospectively tested for susceptibility to pyrazinamide using
the MGIT pyrazinamide kit (pH 5.9) and an inoculum size of
0.5 mL [6]. Test results were then compared with previous
MGIT 960 results for pyrazinamide susceptibility testing
from our database, which had been performed within the
context of routine diagnostic service. Isolates were consid-
ered pyrazinamide resistant if the MGIT 960 testing yielded
concordant resistant results and susceptible if testing yielded
concordant susceptible results. Thirteen isolates with
discordant results were subjected to a third pyrazinamide
susceptibility testing and were sent to an external labora-
tory for conﬁrmation by MGIT testing (ITM, Antwerp,
Belgium). After this second round of testing, concordant
DST results were seen in all isolates (11 resistant, 2
susceptible).
pncA mutation analysis
The entire pncA open reading frame, as well as 133 bp
upstream and 79 bp downstream, were ampliﬁed by PCR, as
described previously [6]. Three experienced technicians
carried out all procedures and readings. Blinding to the
phenotypic reference test could not be guaranteed for every
reading. Non-synonymous pncA mutations (pncA+) were
considered an indicator for pyrazinamide resistance.
Statistical analysis
The primary analysis was the diagnostic accuracy of ﬁnding a
pncA+ isolate in a population of rpoB+ patients (pncA added
to rpoB) to identify pyrazinamide-resistant MDR-TB isolates.
The study population included all patients with an M. tuber-
culosis infection carrying an rpoB mutation. The index test
consisted of pncA sequencing. The MGIT 960 test results for
rifampicin, isoniazid and pyrazinamide were used as the
phenotypic reference test. Only isolates with duplicate
pyrazinamide test results were included in the analysis,
limiting false-resistance results. Inconclusive test results
from the pncA sequencing were grouped with negative
results, because in practice these patients would not
be treated on the basis of mutation analysis but on the
basis of results of the ﬁnal phenotypic susceptibility
tests [11].
Diagnostic accuracy (pncA added to rpoB) was expressed as
sensitivity, speciﬁcity, positive/negative predictive value and
positive/negative likelihood ratios using 2 9 2 contingency
tables and OPENEPI software (version 2.3.1; Rollins School of
Public Health, Emory University; http://www.OpenEpi.com).
The Wilson score method was used to calculate 95% CI
around the proportions. This report was written following
STARD guidelines [12].
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Results
Study population
We identiﬁed 85 patients with a positive M. tuberculosis culture
containing a rpoB mutation (rpoB+ patients), of whom 83 were
enrolled (Fig. 1). The median age of the included patients was
27 years and 43% were males (Table 1). The majority of
patients were foreign-born and 23 patients came from
high-burden MDR-TB countries. One patient was excluded
because no source material was available for pncA sequencing.
This isolate was considered to be pyrazinamide and rifampicin
susceptible, but isoniazid resistant during routine diagnostics.
Another isolate was excluded because no source material was
available for duplicate pyrazinamide phenotypic susceptibility
testing. This latter isolate had been designated as pyrazina-
mide-susceptible, MDR-TB during routine diagnostics.
Phenotypic drug susceptibility testing (reference test)
We detected rifampicin resistance in 72 rpoB+ patients (87%),
isoniazid resistance in 73 rpoB+ patients (88%) and pyrazina-
mide resistance in 32 (39%) rpoB+ patients. MDR-TB was
identiﬁed in 65 rpoB+ patients (78%); isolates of 11 rpoB+
patients proved rifampicin susceptible in the MGIT system.
Most of these isolates carried mutations at speciﬁc codon
positions (Table 2). Phenotypic methods identiﬁed 31 (48%)
pyrazinamide-resistant MDR-TB out of 65 MDR-TB isolates
(phenotypic reference test result).
Diagnostic accuracy of mutation analysis
We performed pncA mutation analysis in all isolates from the
83 rpoB+ patients (Fig. 1). Forty-nine wild-type pncA genes or
genes with synonymous mutations were found, whereas 33
non-synonymous mutations (pncA+) were detected. One test
result was not interpretable; this inconclusive isolate was
85 eligible rpoB+ patients 
Excluded (N = 2):
1x no pncA mutation 
analysis 
1x no duplicate PZA 
MGIT result
83 rpoB+ patients
pncA mutation analysis
(index test)
1 inconclusive result
MGIT 960 
(reference standard)
49 wild type pncA 
or synonymous mutations
MGIT 960 (reference standard)
33 nonsynonymous 
mutations
MGIT 960 
(reference standard)
30 x TP: 
30 PZA-r, MDR-TB 
3 x FP: 
2 PZA-s, MDR-TB
1 PZA-r, Rif-s, INH-r
48 TN:
31 PZA-s, MDR-TB
7 PZA-s, Rif-r, INH-s
7 PZA-s, Rif-s, INH-r
3 PZA-s, Rif-s, INH-s
1x FN:
1 PZA-r, MDR-TB
1 TN:
1 PZA-s, MDR-TB
0 x FN:
-
FIG. 1. Study Algorithm. FN,
false-negative index test result; FP,
false-positive index test result; INH,
isoniazid; MDR-TB, multidrug-resistant
tuberculosis; MGIT, mycobacterial growth
indicator tube; PZA, pyrazinamide; Rif,
rifampicin; rpoB+ patient, patients with a
positive Mycobacterium tuberculosis culture
carrying a mutation in the rpoB gene: -r,
resistant; -s, susceptible; TN, true-negative
index test result; TP, true-positive index
test result.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 1015–1020
CMI Simons et al. Diagnosing pyrazinamide resistance in MDR-TB 1017
classiﬁed as pyrazinamide-susceptible MDR-TB and grouped
with the negative results (see Statistical analysis).
The molecular algorithm based on ﬁnding a pncA mutation in
a population of patients with an rpoB mutation (pncA added to
rpoB mutation) detected 30 of the 31 pyrazinamide-resistant
MDR-TB patients (Fig. 1). Three patients would be incorrectly
labelled as pyrazinamide-resistant MDR-TB. One of the
isolates from these patients proved to be isoniazid- and
pyrazinamide resistant but rifampicin susceptible. This isolate
carried a T deletion at a position 12 bp downstream of the
pncA gene and a Leu511Pro combined with a Met515Leu
mutation in the rpoB gene. The two other isolates, carrying a
Val155Met and an Asp129Asn mutation in the pncA gene, were
classiﬁed as MDR-TB, but were repeatedly pyrazinamide-sus-
ceptible in phenotypic testing. One patient with a pyrazina-
mide-resistant MDR-TB isolate carried a wild type pncA gene
and would be incorrectly labelled as pyrazinamide-susceptible
MDR-TB (Fig. 1). Overall, the sensitivity of the index test
(pncA added to rpoB mutation) for detecting pyrazina-
mide-resistant MDR-TB was 96.8%, the speciﬁcity was 94.2%,
the positive predictive value 90.9%, the negative predictive
value 98.0%, the positive likelihood 16.8 and the negative
likelihood 0.03 (Table 3).
Discussion
In this study we have found that pncA sequencing added to
rpoB mutation analysis can accurately identify pyrazina-
mide-resistant MDR-TB. We showed that sequencing the
pncA gene in M. tuberculosis isolates with an rpoB mutation
had a sensitivity of 97% and speciﬁcity of 94% to detect
pyrazinamide-resistant MDR-TB (Table 3). The rigorous DST
testing to pyrazinamide and our set up as a diagnostic
accuracy study according to STARD guidelines strengthens
the validity of these results. Moreover, our results add to the
growing evidence that screening for mutations in the pncA
gene can be used as a solid proxy for pyrazinamide resistance
in MDR-TB settings [4].
In the present study, we wanted to set up a pragmatic
diagnostic algorithm for high-burden MDR-TB settings, where
screening for MDR-TB is preferably performed using rpoB gene
mutation analysis [1]. That is why this algorithm is different
from our previously published algorithm, which is more
suitable for diagnosing pyrazinamide resistance in low-burden
MDR-TB and pyrazinamide-resistant settings [6]. These two
diagnostic algorithms together may help microbiologists in
standardizing pyrazinamide resistance testing in low-burden as
well as in high-burden MDR-TB settings.
In view of the central role of pyrazinamide in novel (MDR-)
TB treatment regimens, such as in the NC-002 and NC-003
trials (www.tballiance.org), some authors have suggested
stratifying MDR-TB according to pyrazinamide susceptibility
[5]. As such, we propose to perform pncA sequencing in every
isolate with a mutation in the rpoB gene to rapidly and
accurately detect pyrazinamide-resistant MDR-TB (Fig. 1) [5].
Anecdotal evidence suggests that such a strategy, when
TABLE 1. Demographic characteristic of the study patients
All patients (n = 83)
Median age in years (interquartile range) 27 (23–33)
Sex (male) 36 (43%)
Nationality
Foreign-born 78 (94%)
Born in a high-burden multidrug-resistant
tuberculosis (MDR-TB) countrya
23 (28%)
Tuberculosis localization
Pulmonary 56 (67%)
Extrapulmonary 27 (33%)
MDR-TB 65 (78%)
Resistance to pyrazinamideb 32 (39%)
aThe following 27 countries are considered as high-burden MDR-TB countries by
the WHO: Armenia, Azerbaijan, Bangladesh, Belarus, Bulgaria, China, Democratic
Republic of Congo, Estonia, Ethiopia, Georgia, India, Indonesia, Kazakhstan,
Kyrgizstan, Latvia, Lithuania, Myanmar, Nigeria, Pakistan, Philippines, Republic of
Moldova, Russian Federation, South Africa, Tajikistan, Ukraine, Uzbekistan and
Viet Nam.
bThirty-one isolates were pyrazinamide-resistant MDR-TB. One isolate was
pyrazinamide-resistant, isoniazid-resistant but rifampicin-susceptible.
TABLE 2. Association of non-synonymous mutations in the rpoB or pncA gene with phenotypic drug susceptibility (DST) to
either rifampicin or pyrazinamide
Drug Locus DSTa Mutationb
Pyrazinamide pncA Resistant Met1Ile, Met1Thr, Ala28Thr, Ala46Val, Thr47Ala, Asp49Glu, His51Arg, His57Tyr, Pro62Leu,
Pro69Ser, Thr76Pro, Leu85Arg, Phe94Cys, Gly97Arg, Tyr103stop, Ser104Arg, Thr135Pro,
Thr168Pro, Met175Ile, Val180Phe, Leu182Ser
Susceptible Asp129Asn, Val155Met
Rifampicin rpoB Resistant Leu449Arg,c Asp516Ala, Asp516Val, Asp516Tyr,d Pro520Ser,c Ser522Leu, His526Ala,
His526Asp, His526Leu,d His526Tyr, Ser531Leu, Ser531Met, Ser531Phe, Leu533Proc
Susceptible Leu511Pro, Met515Leu,c Asp516Tyr,d His526Asn, His526Leu,d Ser531Cys, Leu533Prod
aDrug susceptibility was tested using the MGIT 960 system. Susceptibility to pyrazinamide was tested in duplicate.
bThe pncA mutations not found in the DreamDB database (http://www.tbdreamdb.com) are highlighted in bold.
cThe following mutations were only seen in combination with other mutations: Leu449Arg with His526Leu, Met515Leu with Leu511Pro, Pro520Ser with Ser522Leu and
Leu533Pro with Asp516Ala.
dThe following mutations were noted both in susceptible as well as in resistant cases: Asp516Tyr (one susceptible, one resistant), His526Leu (three susceptible, one resistant) and
Leu533Pro (one susceptible, two resistant in combination with Asp516Ala).
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performed on direct sputum samples, may give accurate
results within days [13].
Other researchers have found lower proportions (between
72 and 88%) of non-synonymous mutations in pyrazina-
mide-resistant strains highlighting the risk of false susceptibility,
e.g. pyrazinamide resistance in wild-type pncA [6,14,15].
However, contrary to our study, these studies were not
designed as diagnostic accuracy studies, did not re-test isolates
in the MGIT 960 system, or were not performed in an
MDR-TB population [5]. The occurrence of mutations in other
genes, such as in the recently described rpsA gene and panD
gene, could also explain why others found higher numbers of
pyrazinamide-resistant isolates without pncA mutations
[16,17]. In the present study, we did not systematically test
for these mutations, because we rarely found pyrazina-
mide-resistant isolates with wild-type pncA and the clinical
signiﬁcance of these alternative mutations in routine pyrazin-
amide diagnostics is yet to be determined [18].
Contrary to our expectations, we noted that mutations in
the rpoB gene were not a perfect predictor for MDR-TB
(Fig. 1). On the one hand, we saw some rifampicin
monoresistant isolates. This could be caused by the fact
that our rpoB+ patients were drawn from a population with
low levels of rifampicin resistance. It has been shown
previously that in such situations rpoB mutations have a low
positive predictive value for detecting MDR-TB [19]. On the
other hand, we noted that around 10% of rpoB mutations
recorded in this study gave rise to a rifampicin-susceptible
phenotype in the MGIT system. These rpoB mutations were
mostly at speciﬁc positions of the rpoB gene (Table 2) that
have been associated with discordant results for rifampicin
in the MGIT 960 system [20]. These speciﬁc mutations
probably give rise to MICs for rifampicin that lay around its
break point concentration, thereby leading to so-called
low-level, or intermediate, rifampicin-resistant strains
[20,21]. This marks a ﬂaw inherent in determining rifampicin
susceptibility by rapid phenotypic DST assays, testing only at
the breakpoint concentration. This is an important ﬁnding
that poses a therapeutic challenge because the mutations
that yield low-level resistance have been associated with
treatment failures and relapse [22,23].
In the present study, we presupposed that all pncA
mutations were in fact resistance-determining mutations.
And indeed, most of the pncA mutations seen in this study
(Table 2) are in agreement with the resistance-determining
mutations found in the DREAMDB database (http://www.
tbdreamdb.com, accessed 17 February 2014), seven of which
are listed as high conﬁdence for being resistance-determining
[24]. Seven mutations have not been described previously
and two mutations—Thr168Pro and Met175Ile—were found
in other publications (Table 2) [25,26]. The Met175Ile
mutation has previously been associated with both
susceptible and resistant pyrazinamide strains [25]. Stoffels
and co-workers have shown that these types of mutations
encode for low-level pyrazinamide resistance [25], explaining
why they might not be adequately detected using the MGIT
960 system. Low-level pyrazinamide resistance not detected
by the MGIT system might also explain why we found two
non-synonymous pncA mutations in pyrazinamide-suscepti-
ble strains (Table 2). On the other hand, these two
need not be resistance-determining mutations; pncA
mutant, but pyrazinamide-susceptible isolates are occasion-
ally seen.
Many factors interplay in a real-life diagnostic testing
strategy and the present study should be cautiously inter-
preted as such owing to its design. First, some bias may
have been introduced by the retrospective nature of our
study using archived samples. Second, though the rigorous
DST for pyrazinamide did strengthen the validity of our
MGIT 960 results, such a strategy is probably not feasible in
routine diagnostics. Third, we performed indirect molecular
DST using M. tuberculosis cultures, whereas in practice it
would have been preferable to perform the molecular
analysis directly on sputum samples. Future studies should
examine the performance of this technique in programmatic
settings.
In conclusion, we found that diagnosing pyrazina-
mide-resistant MDR-TB by rapid molecular assays is highly
accurate. We therefore propose to include pncA sequencing
for every M. tuberculosis isolate with a mutation in the rpoB
gene. This makes it possible to stratify MDR-TB according
to pyrazinamide susceptibility, thereby paving the way for
the urgently needed treatment efﬁcacy studies within this
population.
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TABLE 3. Diagnostic accuracy of pncA sequencing added to
rpoB mutation analysis for diagnosing pyrazinamide-resistant
MDR-TB
Estimate 95% CI
Sensitivity 96.8 83.8–99.4
Speciﬁcity 94.2 84.4–98.0
Positive predictive value 90.9 76.4–96.9
Negative predictive value 98.0 89.5–99.7
Positive likelihood ratio 16.8 8.7–32.3
Negative likelihood ratio 0.03 0.005–0.2
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